Nishimoto N - Search Results

1

The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.

Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E, Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. Chang Q, et al. Among authors: nishimoto n. Neoplasia. 2013 Jul;15(7):848-62. doi: 10.1593/neo.13706. Neoplasia. 2013. PMID: 23814496 Free PMC article.

2

Therapeutic adenoviral gene transfer of a glycosyltransferase for prevention of peritoneal dissemination and metastasis of gastric cancer.

Kawamura YI, Adachi Y, Curiel DT, Kawashima R, Kannagi R, Nishimoto N, Dohi T. Kawamura YI, et al. Among authors: nishimoto n. Cancer Gene Ther. 2014 Oct;21(10):427-33. doi: 10.1038/cgt.2014.46. Epub 2014 Sep 12. Cancer Gene Ther. 2014. PMID: 25213663

3

The paradigm of IL-6: from basic science to medicine.

Naka T, Nishimoto N, Kishimoto T. Naka T, et al. Among authors: nishimoto n. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S233-42. doi: 10.1186/ar565. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110143 Free PMC article. Review.

4

Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas.

Adachi Y, Aoki C, Yoshio-Hoshino N, Takayama K, Curiel DT, Nishimoto N. Adachi Y, et al. Among authors: nishimoto n. Int J Cancer. 2006 Sep 15;119(6):1303-11. doi: 10.1002/ijc.22006. Int J Cancer. 2006. PMID: 16642474 Free article.

5

Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells.

Yamamoto M, Nishimoto N, Davydova J, Kishimoto T, Curiel DT. Yamamoto M, et al. Among authors: nishimoto n. Cancer Gene Ther. 2006 Feb;13(2):194-202. doi: 10.1038/sj.cgt.7700873. Cancer Gene Ther. 2006. PMID: 16082380

6

VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery.

Adachi Y, Yoshio-Hoshino N, Aoki C, Nishimoto N. Adachi Y, et al. Among authors: nishimoto n. Anticancer Res. 2010 Jun;30(6):1947-52. Anticancer Res. 2010. PMID: 20651338

7

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Nakahara H, et al. Among authors: nishimoto n. Arthritis Rheum. 2003 Jun;48(6):1521-9. doi: 10.1002/art.11143. Arthritis Rheum. 2003. PMID: 12794819 Free article.

8

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Nishimoto N, et al. Arthritis Rheum. 2004 Jun;50(6):1761-9. doi: 10.1002/art.20303. Arthritis Rheum. 2004. PMID: 15188351 Free article. Clinical Trial.

9

Inhibition of IL-6 for the treatment of inflammatory diseases.

Nishimoto N, Kishimoto T. Nishimoto N, et al. Curr Opin Pharmacol. 2004 Aug;4(4):386-91. doi: 10.1016/j.coph.2004.03.005. Curr Opin Pharmacol. 2004. PMID: 15251133 Review.

10

Interleukin 6: from bench to bedside.

Nishimoto N, Kishimoto T. Nishimoto N, et al. Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26. doi: 10.1038/ncprheum0338. Nat Clin Pract Rheumatol. 2006. PMID: 17075601 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page